Drugs / MRT5413
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05650554 | Dec 2022 → Apr 2024 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRT5413 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650554 ↗ |
| Modality | Messenger RNA (mRNA) | “Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5413” NCT05650554 ↗ |
| Route | Intramuscular | “Route of Administration: Intramuscular injection” NCT05650554 ↗ |